Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BG-C477 + chemotherapy
- Development stage
- Unknown
- Lead developer
- BeOne Medicines
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BG-C477 + chemotherapy is a combination therapy being investigated for the treatment of advanced, metastatic, or unresectable solid tumors. The combination consists of BG-C477, an antibody-drug conjugate (ADC) targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5, also known as CEA), and various systemic chemotherapy agents. BG-C477 is designed to selectively deliver a cytotoxic payload to tumor cells overexpressing CEACAM5, a protein frequently found in gastrointestinal and non-small cell lung cancers, while having limited expression on normal tissues. The addition of chemotherapy is intended to provide synergistic antitumor activity. This combination is currently being evaluated in a Phase 1a/b multicenter, open-label, first-in-human study (NCT06596473) to assess safety, tolerability, pharmacokinetics, and preliminary efficacy in patients who have progressed on at least two prior lines of standard systemic therapy.
- Other names
- BG-C477 in combination with chemotherapyBG-C-477 in combination with chemotherapyBG-C 477 in combination with chemotherapy
02
Targets
TOP1 (DNA Topoisomerase I)CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)
Beyond the preview
Go deeper on BG-C477 + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BG-C477 + chemotherapy.